Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma
Journal of Clinical Oncology · 01.03.2024 · 42 (7) · 790-799
DOI: 10.1200/jco.23.00757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.03.2024. Verfasst von Daniel Q Huang und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis C, Hepatitis B. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
PURPOSE There are limited data on antiviral treatment utilization and its impact on long-term outcomes of hepatitis B virus (HBV)– and hepatitis C virus (HCV)–related hepatocellular carcinoma (HCC) after hepatic resection. We aimed to determine the utilization and impact of antivirals in HBV- and HCV-related HCC. METHODS This cohort study included 1,906 participants (1,054 HBV-related HCC and 852 HCV-related HCC) from 12 international sites. All participants had HBV- or HCV-related HCC and underwent curative surgical resection. The primary outcome was the utilization of antiviral therapy, and the secondary outcome was long-term overall survival (OS). RESULTS The mean (±standard deviation [SD]) age was 62.1 (±11.3) years, 74% were male, and 84% were Asian. A total of 47% of the total cohort received antiviral therapy during a mean (±SD) follow-up of 5.0 (±4.3) years. The overall antiviral utilization for participants with HBV-related HCC was 57% and declined over time, from 65% before 2010, to 60% from 2010 to 2015, to 47% beyond 2015, P < .0001. The overall utilization of antivirals for HCV-related HCC was 35% and increased over time, from 24% before 2015 to 74% from 2015 and beyond, P < .0001. The 10-year OS was lower in untreated participants for both HBV (58% v 61%) and HCV participants (38% v 82%; both P < .0001). On multivariable Cox regression analysis adjusted for relevant confounders, antiviral therapy initiated before or within 6 months of HCC diagnosis was independently associated with lower mortality in both HBV- (adjusted hazard ratio [aHR], 0.60 [95% CI, 0.43 to 0.83]; P = .002) and HCV-related HCC (aHR, 0.18 [95% CI, 0.11 to 0.31]; P < .0001). CONCLUSION Antiviral therapy is associated with long-term survival in people with HBV- or HCV-related HCC who undergo curative resection but is severely underutilized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Division of Gastroenterology and Hepatology, National University Health System, Singapore, Singapore.
- Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA.
- Meharry Medical College, Nashville, TN.
- Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- Hepatitis Research Center, College of Medicine and Cohort Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.
ORCID-Profile: Daniel Q Huang, Rubayet Kamal, Pei-Chien Tsai, Hidenori Toyoda, Ming-Lun Yeh, Dae Won Jun, Yasuhito Tanaka, Haruki Uojima, Eiichi Ogawa, Ju Dong Yang, Joanne K Liu, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Yock Young Dan, Carlos Esquivel, Andrew Bonham, Ming-Lung Yu, Mindie H Nguyen
Zitieren
APA
Huang, D. Q., Hoang, J. K., Kamal, R., Tsai, P. C., Toyoda, H., Yeh, M. L., Yasuda, S., Leong, J., Maeda, M., Huang, C. F., Won Jun, D., Ishigami, M., Tanaka, Y., Uojima, H., Ogawa, E., Abe, H., Hsu, Y. C., Tseng, C. H., Alsudaney, M., …, & Nguyen, M. H. (2024). Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma. Journal of Clinical Oncology, 42(7), 790-799. https://doi.org/10.1200/jco.23.00757
Vancouver
Huang DQ, Hoang JK, Kamal R, Tsai PC, Toyoda H, Yeh ML, et al. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma. Journal of Clinical Oncology. 2024;42(7):790-799. doi:10.1200/jco.23.00757
BibTeX
@article{Huang2024,
author = {Huang, Daniel Q and Hoang, Joseph K and Kamal, Rubayet and Tsai, Pei-Chien and Toyoda, Hidenori and Yeh, Ming-Lun and Yasuda, Satoshi and Leong, Jennifer and Maeda, Mayumi and Huang, Chung-Feng and Won Jun, Dae and Ishigami, Masatoshi and Tanaka, Yasuhito and Uojima, Haruki and Ogawa, Eiichi and Abe, Hiroshi and Hsu, Yao-Chun and Tseng, Cheng-Hao and Alsudaney, Manaf and Yang, Ju Dong and Yoshimaru, Yoko and Suzuki, Takanori and Liu, Joanne K and Landis, Charles and Dai, Chia-Yen and Huang, Jee-Fu and Chuang, Wan-Long and Schwartz, Myron and Dan, Yock Young and Esquivel, Carlos and Bonham, Andrew and Yu, Ming-Lung and Nguyen, Mindie H},
title = {Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {7},
pages = {790--799},
doi = {10.1200/jco.23.00757}
}
EUVIMED